- Home
- TGL vs TOVX Comparison
TGL vs TOVX Comparison
Compare TGL & TOVX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TGL
- TOVX
- Stock Information
- Founded
- TGL 2020
- TOVX 2001
- Country
- TGL United States
- TOVX United States
- Employees
- TGL N/A
- TOVX N/A
- Industry
- TGL Retail: Computer Software & Peripheral Equipment
- TOVX Biotechnology: Pharmaceutical Preparations
- Sector
- TGL Technology
- TOVX Health Care
- Exchange
- TGL Nasdaq
- TOVX Nasdaq
- Market Cap
- TGL 4.1M
- TOVX 3.8M
- IPO Year
- TGL 2022
- TOVX 2006
- Fundamental
- Price
- TGL $0.85
- TOVX $0.31
- Analyst Decision
- TGL
- TOVX Hold
- Analyst Count
- TGL 0
- TOVX 1
- Target Price
- TGL N/A
- TOVX N/A
- AVG Volume (30 Days)
- TGL 5.7M
- TOVX 44.4M
- Earning Date
- TGL 10-15-2025
- TOVX 11-11-2025
- Dividend Yield
- TGL N/A
- TOVX N/A
- EPS Growth
- TGL N/A
- TOVX N/A
- EPS
- TGL N/A
- TOVX N/A
- Revenue
- TGL $2,330,557.00
- TOVX N/A
- Revenue This Year
- TGL N/A
- TOVX N/A
- Revenue Next Year
- TGL N/A
- TOVX N/A
- P/E Ratio
- TGL N/A
- TOVX N/A
- Revenue Growth
- TGL N/A
- TOVX N/A
- 52 Week Low
- TGL $0.68
- TOVX $0.28
- 52 Week High
- TGL $39.00
- TOVX $2.64
- Technical
- Relative Strength Index (RSI)
- TGL 44.91
- TOVX 43.61
- Support Level
- TGL $0.69
- TOVX $0.29
- Resistance Level
- TGL $1.17
- TOVX $0.35
- Average True Range (ATR)
- TGL 0.10
- TOVX 0.11
- MACD
- TGL -0.00
- TOVX -0.01
- Stochastic Oscillator
- TGL 33.98
- TOVX 5.07
About TGL Treasure Global Inc.
Treasure Global Inc has created an online-to-offline e-commerce platform business model offering consumers and merchants instant rebates and affiliate cashback programs, while providing a seamless e-payment solution with rebates in both e-commerce and physical retailers/merchant settings. Its product is an internet application branded ZCITY app, that targets consumers by providing personalized deals based on consumers' purchase history, location and preferences.
About TOVX Theriva Biologics Inc.
Theriva Biologics Inc is a clinical-stage pharmaceutical company developing a novel oncolytic adenovirus (OV) platform to address devastating cancers with high unmet needs. It is a clinical-stage program VCN-01, designed to break down the tumor stroma, and its preclinical-stage program VCN-11 leverages its proprietary Albumin Shield Technology to protect systemically administered oncolytic viruses from the host immune system.